Can pregabalin be used for chronic cough in interstitial lung disease?

Pregabalin for Chronic Cough in ILD

Yes, pregabalin can be used for refractory chronic cough in interstitial lung disease (ILD) when standard treatments have failed, following the approach recommended for unexplained chronic cough. The 2018 CHEST guidelines specifically suggest trials of neuromodulators like gabapentin (and by extension pregabalin, which has similar mechanisms) for ILD-associated refractory chronic cough 1.

Clinical Approach

When to Consider Pregabalin

Before initiating pregabalin, you must:

• Rule out treatable causes first: Assess for ILD progression, immunosuppressive drug side effects, pulmonary infections, and evaluate for gastroesophageal reflux, upper airway cough syndrome, and asthma according to standard chronic cough guidelines 1
• Confirm the cough is refractory: Standard treatments targeting underlying causes have failed
• Document quality of life impairment: The cough must be significantly affecting the patient's daily functioning

Evidence Supporting Use

The CHEST guideline panel explicitly recommends following their unexplained chronic cough guideline for ILD patients with refractory cough, which includes neuromodulators like gabapentin 1. While the guideline specifically mentions gabapentin, pregabalin operates through the same mechanism (α2δ ligand binding) and has demonstrated efficacy in chronic cough studies.

Research evidence shows pregabalin works:

• Combined pregabalin (300 mg daily) with speech pathology therapy significantly improved cough severity (mean difference 25.1 on visual analog scale) and quality of life (mean difference 3.5 on Leicester Cough Questionnaire) compared to speech pathology alone 2
• A 2023 pilot trial in resistant subacute/chronic cough showed pregabalin increased quality of life scores and achieved ≥70% recovery in 26% of patients 3
• Systematic reviews confirm neuromodulators including pregabalin reduce cough frequency and improve quality of life in refractory chronic cough 4, 5

Practical Implementation

Dosing strategy:

• Start pregabalin at 75 mg twice daily
• Titrate to 150 mg twice daily (300 mg total daily dose) based on response and tolerability
• The effective dose in the strongest trial was 300 mg daily 2

Combination therapy is superior:

• Pregabalin works best when combined with multimodality speech pathology therapy rather than as monotherapy 2
• Consider referral to speech pathology for cough suppression techniques and behavioral interventions

Monitor for common adverse effects (from FDA labeling 6):

• Dizziness (21-26% incidence)
• Somnolence (12-16% incidence)
• Peripheral edema (9% incidence)
• Weight gain (4% incidence)

Important Caveats

Pregabalin is not FDA-approved for cough - this is off-label use 6. The FDA labeling covers neuropathic pain, fibromyalgia, and seizures, but the mechanism (neural pathway inhibition) is relevant to cough hypersensitivity.

Watch for serious reactions 6:

• Angioedema (can be life-threatening) - discontinue immediately if facial/throat swelling occurs
• Increased suicidal ideation risk (as with all antiepileptic drugs)
• Hypersensitivity reactions

The guideline notes gabapentin specifically, not pregabalin 1. However, pregabalin has advantages: better bioavailability, more predictable pharmacokinetics, and twice-daily rather than three-times-daily dosing, making it a reasonable alternative.

Escalation Strategy

If pregabalin fails or is not tolerated:

• The CHEST guidelines suggest opiates for palliative symptom control when alternative treatments have failed and cough severely affects quality of life 1
• Reassess benefits and risks at 1 week, then monthly before continuing opiates
• Consider clinical trial enrollment if available

What NOT to Do

Do not use inhaled corticosteroids for cough in pulmonary sarcoidosis (Grade 2C recommendation) 1

Do not prescribe proton pump inhibitors for IPF patients with chronic cough and negative GERD workup 1

The evidence base for ILD-associated cough treatment remains limited 1, but pregabalin represents a rational, guideline-supported approach for refractory cases where quality of life is significantly impaired. The key is proper patient selection after excluding treatable causes and combining pharmacologic treatment with behavioral interventions.